Nucleic-acid-based detection |
Reverse transcriptase polymerase chain reaction (RT-PCR) |
Range of assays for selected diagnoses |
Reverse transcription of CTC-specific mRNA to complementary DNA (cDNA) followed by PCR-amplification of cDNA |
- |
Blood, bone marrow, tissue, and other biological samples |
High sensitivity |
RNA instability, illegitimate expression, and false positivity; does not allow isolation of viable cells |
[2,62,64] |
Cytometry-based detection |
Immunocytochemistry (ICC) |
Range of assays for selected diagnoses |
Antibody staining of tumor-specific antigens |
Chosen based on proteins expressed in primary tumors |
Blood, bone marrow, tissue, and other biological samples |
Can be conjugated with automated imaging system |
Limited number of cells evaluated, risks of cross-reactions with other epitopes, low sensitivity |
[70,71] |
Flow cytometry (FC) |
Range of assays for selected diagnoses |
Quantification of surface and intracellular antigens using antibodies conjugated with fluorescent dye |
Chosen based on proteins expressed in primary tumors |
Blood, bone marrow, tissue, and other biological samples |
Ability to measure multiple parameters of large numbers of cells relatively quickly. Cells can be isolated for further analysis |
Low sensitivity, time-consuming |
[72] |
Automated digital microscopy (ADM) |
- |
Fluorescence microscopy and robotic motion control system to automate imaging |
Antibodies against tumor-specific biomarkers |
Blood |
Identification of very rare epithelial cells in whole blood samples |
Enrichment step needed, long exposure time (800 cells/s) |
[75,77] |
Fiber-optic array scanning technology (FAST) |
FASTcell™ (SRI International, Menlo Park, CA, USA) |
Image analysis of immunocytochemically labeled tumor cells |
Antibodies to tumor-specific biomarkers |
Blood |
Does not require enrichment step |
Special type of cytometer needed |
[75,76,77] |
Microscopy-based detection |
Fluorescence microscopy |
Range of assays for selected diagnoses, e.g., CytoTrack® (Cytotrack Aps, Lyngby, Denmark), RareCyte® (RareCyte, Inc., Seattle, WA, USA) |
Optical microscopic examination of cells stained immunologically |
Based on genes expressed in primary tumors, e.g., Anti-EpCAM and cytokeratins |
Blood, bone marrow, tissue, other biological samples |
Enrichment-free; automated microscopic imaging system; possibility of single-cell retrieval and further molecular characterization of CTCs; can be used for non-epithelial cells |
Limited observation time, manual assessment necessary; long processing time; isolated cells are not viable |
[11,25,79] |